BIOLASE Technology, Inc. Announces Distribution Agreements in China

IRVINE, CA--(Marketwire - September 28, 2009) - BIOLASE Technology, Inc. (NASDAQ: BLTI) today announced that it finalized three regional distribution agreements in the People’s Republic of China. This announcement follows the Company’s August 12, 2009, announcement that it had received regulatory approval to market its Waterlase MD™ products in China.

“Three regional agreements were signed in China with partners who have gained our strong confidence,” David M. Mulder, Chief Executive Officer said. The first agreement was with Shanghai Haopu Medical Instruments Co., Ltd. (Haopu) for primarily the eastern Chinese provinces and municipalities of Anhui, Fujian, Henan, Jiangsu, Jiangxi, Shandong, Shanghai and Zhejiang. Haopu is a dynamic young company with eight years of business development experience and a good reputation for customer satisfaction from their service and clinical education programs in the East China region. Mulder continued, “Haopu worked with us closely on the Chinese registration process and we very much appreciate their assistance, and look forward to moving forward together.”

The second agreement is with Beijing E-Maxdent Company (E-Maxdent), covering primarily the Northern provinces and municipalities of Beijing, Gansu, Hebei, Heilongjian, Jilin, Liaoning, Qinghai, Shaanxi, Tianjin, Nei Mongol, Ningxia, Tibet and Xinjiang. Mulder said, “The principals of E-Maxdent are all dentists. They share our passion for delivering better dentistry around the world. They currently distribute other high tech dentistry equipment in North China and felt the addition of the leading dental laser brand in the world was critical to that offering.”

The third agreement was with Advanced Medical Technology China Ltd. (Advanced) for primarily the southern provinces and municipalities of Guangdong, Guangxi, Hainan, Yunnan, Hunan, Guizhou, Sichuan, Chongqing and Hubei. Mulder continued, “We have worked with the principals of Advanced very successfully in Hong Kong, and they have pre-established operations on the mainland where we are very excited about extending our partnership.”

“We have already started working on some initial demonstration unit orders, training and marketing plans. We expect a six- to nine-month ramp-up period and look forward to a promising future in China,” Mulder concluded. Contact information for the three distributors is currently being added to the Company’s website at www.biolase.com.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world’s leading dental laser company, develops, manufactures and markets Waterlase technology and lasers and related products that advance the practice of dentistry and medicine. The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with reduced pain, faster and biological recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology, pain management and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company’s actual results to differ materially from the statements contained herein, and are described in the Company’s reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.